| Name | Title | Contact Details |
|---|
Clinical trials are designed around endpoints, but its the beginning that sets them up for success—including selecting the best RTSM partner for continuous and flexible support throughout the duration of a trial. With decades of experience, Endpoint Clinical is obsessed with proactive problem-solving, ensuring that issues are anticipated and resolved before they escalate, and any changes are easily incorporated. From day one, we become an extension of your team, seamlessly integrating into your trial operations. We minimize friction, reduce risk, and enable your clinical teams to focus where it matters most—on trial success. Endpoint is headquartered in Raleigh, NC, with offices across the US, EU, and Asia.
The Valens Company (TSX:VLNS) (OTCQX:VLNCF) is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development. The Valens Company is the largest third-party extraction Company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. Additionally, our subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science.
Semler Research Center Pvt. Ltd. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Seed Health is a microbial sciences company pioneering applications of microbes for human and planetary health. In collaboration with leading academic researchers, we advance breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics, consumer health innovations and environmental solutions.
Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`